Novo Nordisk A/S (NYSE:NVO) Given Average Rating of “Buy” by Analysts

Shares of Novo Nordisk A/S (NYSE:NVOGet Rating) have received a consensus rating of “Hold” from the nineteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $552.80.

Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Novo Nordisk A/S from 850.00 to 900.00 in a research note on Wednesday, May 4th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating in a research note on Tuesday, April 12th. Stifel Nicolaus started coverage on shares of Novo Nordisk A/S in a research note on Monday, February 28th. They issued a “buy” rating on the stock. StockNews.com started coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Finally, Barclays upped their price target on shares of Novo Nordisk A/S from 750.00 to 850.00 in a research note on Thursday, April 14th.

A number of institutional investors have recently bought and sold shares of NVO. WCM Investment Management LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $278,383,000. Two Sigma Advisers LP boosted its holdings in Novo Nordisk A/S by 345.8% during the third quarter. Two Sigma Advisers LP now owns 715,900 shares of the company’s stock valued at $68,734,000 after acquiring an additional 555,300 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Novo Nordisk A/S during the fourth quarter valued at about $58,800,000. Vantage Investment Partners LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $54,316,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Novo Nordisk A/S during the third quarter valued at about $37,246,000.

Shares of NYSE:NVO opened at $111.35 on Monday. The company’s fifty day moving average is $110.94 and its two-hundred day moving average is $107.82. The company has a quick ratio of 0.66, a current ratio of 0.91 and a debt-to-equity ratio of 0.36. Novo Nordisk A/S has a 12-month low of $75.04 and a 12-month high of $122.16. The company has a market cap of $262.21 billion, a P/E ratio of 33.14, a price-to-earnings-growth ratio of 2.29 and a beta of 0.47.

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 5th. Shareholders of record on Monday, March 28th were given a dividend of $0.741 per share. This represents a yield of 1.1%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. The ex-dividend date of this dividend was Friday, March 25th. Novo Nordisk A/S’s dividend payout ratio is presently 44.05%.

About Novo Nordisk A/S (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Featured Stories

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.